Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles tagged with "outcome"

The ACR’s State-of-the-Art Clinical Symposium: Experts Discuss Jakinibs, Osteoarthritis, Membranous Lupus Nephritis

Thomas R. Collins  |  July 14, 2015

CHICAGO—With the approval of the Jak inhibitors (i.e., jakinibs) tofacitinib and ruxolitinib—and others being investigated—rheumatologists need to arm themselves with an understanding of these drugs so they can think critically when evaluating them and deciding how to use them, said John O’Shea, MD, chief of the Molecular Immunology and Inflammation Branch of and scientific director…

The ACR’s State-of-the-Art Clinical Symposium: Rheumatologists Weigh in on Tough-to-Treat Cases, Paget’s Disease, Imaging

Thomas R. Collins  |  July 14, 2015

CHICAGO—A 49-year-old woman has had RA for eight years. She has a rheumatoid factor reading of 35, an aCCP reading of 160, erythrocyte sedimentation rate of 42, plus erosions. She has been on methotrexate. She tried etanercept for six months, but then it stopped working. She was on 40 mg of adalimumab weekly, but it…

Adverse Event Risk Data Drive Evaluation of Psoriasis Treatments

Michele B. Kaufman, PharmD, CGP, RPh  |  July 14, 2015

PSOLAR, the Psoriasis Longitudinal Assessment and Registry, is a multicenter, longitudinal, intercontinental, disease-based registry used to identify adverse events from commonly used psoriasis drugs.1 An evaluation of the risk of serious infection from systemic psoriasis treatments was recently published using data from PSOLAR. Ninety-three institutional review boards or ethics committees reported into the registry from…

Zoledronic Acid May Improve Bone Density in Elderly Women

Anne Harding (Reuters Health)  |  June 15, 2015

A single injection daily of zoledronic acid may improve bone mineral density (BMD) in frail elderly women in long-term care facilities, a new randomized controlled trial shows. However, the clinical importance of the improvement, observed over a two-year period, remains unclear, Dr. Neil M. Resnick, of the University of Pittsburgh, told Reuters Health in a…

Lyme Disease Not Predictor of Long-Term Physical, Mental Health Issues

Lara C. Pullen, PhD  |  May 22, 2015

Lyme disease is often considered a cause of chronic fatigue, pain and other incapacitating symptoms. This assumption stems from analyses of patients who seek retreatment for Lyme disease. However, a new study suggests that Lyme disease is not life altering in the long term for most patients. Specifically, patients with culture-confirmed Lyme disease have similar…

2014 ACR/ARHP Annual Meeting: Methotrexate Use in Patients with RA

Susan Bernstein  |  April 1, 2015

Review of clinical research on methotrexate therapy, effect on patients’ functionality, tolerability, adverse events

Value of Patient Care Services in Rheumatology Gets Boost

E. William St.Clair  |  April 1, 2015

By developing guidelines, quality measures, data on patient outcomes, the ACR helps rheumatologists translate the value of their work to the world

Patient’s Journey with Rheumatoid Arthritis Redefines ‘Treat to Target’

Gretchen Henkel  |  March 1, 2015

Rheumatologist Richard Brasington, MD, says patient John Reigstad’s active participation in treatment decisions shows how much improving quality of life matters

Does Gastric Bypass Result in Reduced Absorption of Methotrexate?

Iris Zink, NP  |  March 1, 2015

Data suggest changes in physiology of the gut post-bariatric surgery may result in medication malabsorption of immunosuppressive drugs

2014 ACR/ARHP Annual Meeting: Seeking the Patient Perspective in Real-World Settings

Kathy Holliman  |  February 1, 2015

Pediatricians discuss role of patient-centered outcomes in learning health centers

  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences